| __timestamp | Alnylam Pharmaceuticals, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 3852327 |
| Thursday, January 1, 2015 | 60610000 | 839656 |
| Friday, January 1, 2016 | 89354000 | 4478145 |
| Sunday, January 1, 2017 | 199365000 | 16432324 |
| Monday, January 1, 2018 | 382359000 | 11890871 |
| Tuesday, January 1, 2019 | 479005000 | 34110000 |
| Wednesday, January 1, 2020 | 588420000 | 35781000 |
| Friday, January 1, 2021 | 620639000 | 40896000 |
| Saturday, January 1, 2022 | 770658000 | 52200000 |
| Sunday, January 1, 2023 | 795646000 | 59836000 |
| Monday, January 1, 2024 | 975526000 |
Infusing magic into the data realm
In the competitive world of biotechnology, effective cost management is crucial for success. Alnylam Pharmaceuticals, Inc. and Merus N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Merus N.V. maintained a more conservative approach, with expenses increasing by approximately 1,500% during the same period.
These trends highlight the diverse strategies employed by biotech firms in managing operational costs while pursuing innovation.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Teva Pharmaceutical Industries Limited and Merus N.V.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Merus N.V.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Merus N.V.
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Merus N.V.
Perrigo Company plc and Merus N.V.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Merus N.V. and MannKind Corporation
Merus N.V. vs Dynavax Technologies Corporation: SG&A Expense Trends